"RNA, Messenger" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
| Descriptor ID |
D012333
|
| MeSH Number(s) |
D13.444.735.544
|
| Concept/Terms |
mRNA, Polyadenylated- mRNA, Polyadenylated
- RNA, Messenger, Polyadenylated
- Messenger RNA, Polyadenylated
- Polyadenylated Messenger RNA
- RNA, Polyadenylated Messenger
- Polyadenylated mRNA
- Poly(A)+ mRNA
|
Below are MeSH descriptors whose meaning is more general than "RNA, Messenger".
Below are MeSH descriptors whose meaning is more specific than "RNA, Messenger".
This graph shows the total number of publications written about "RNA, Messenger" by people in this website by year, and whether "RNA, Messenger" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 6 | 3 | 9 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 6 | 6 |
| 1998 | 0 | 3 | 3 |
| 1999 | 3 | 3 | 6 |
| 2000 | 1 | 2 | 3 |
| 2001 | 2 | 5 | 7 |
| 2002 | 0 | 7 | 7 |
| 2003 | 1 | 8 | 9 |
| 2004 | 0 | 11 | 11 |
| 2005 | 1 | 17 | 18 |
| 2006 | 2 | 15 | 17 |
| 2007 | 2 | 11 | 13 |
| 2008 | 3 | 11 | 14 |
| 2009 | 3 | 13 | 16 |
| 2010 | 1 | 15 | 16 |
| 2011 | 2 | 11 | 13 |
| 2012 | 0 | 8 | 8 |
| 2013 | 0 | 17 | 17 |
| 2014 | 1 | 9 | 10 |
| 2015 | 1 | 18 | 19 |
| 2016 | 2 | 11 | 13 |
| 2017 | 65 | 206 | 271 |
| 2018 | 33 | 138 | 171 |
| 2019 | 13 | 54 | 67 |
| 2020 | 18 | 23 | 41 |
| 2021 | 23 | 137 | 160 |
| 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "RNA, Messenger" by people in Profiles.
-
Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients. J Natl Cancer Inst. 2022 Feb 07; 114(2):203-209.
-
Myeloperoxidase anti-neutrophil cytoplasmic antibody positive optic perineuritis after mRNA coronavirus disease-19 vaccine. QJM. 2021 12 20; 114(10):737-738.
-
68Ga-DOTATOC-avid lymphadenopathies induced from COVID-19 mRNA vaccination. Jpn J Clin Oncol. 2021 12 01; 51(12):1765.
-
Guillain-Barré Syndrome After COVID-19 mRNA Vaccination in a Liver Transplantation Recipient With Favorable Treatment Response. Liver Transpl. 2022 01; 28(1):134-137.
-
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. AIDS. 2021 11 15; 35(14):2399-2401.
-
Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc. 2021 Nov 11; 10(10):937-939.
-
Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report. Acta Derm Venereol. 2021 11 10; 101(11):adv00589.
-
Neuralgic amyotrophy following COVID-19 mRNA vaccination. QJM. 2021 11 05; 114(7):503-505.
-
Anti-SARS-CoV-2 IgA Response in Baseline Seronegative and Seropositive Recipients of BNT162b2 mRNA COVID-19 Vaccine. J Occup Environ Med. 2021 11 01; 63(11):e829.
-
Immune Response Post-SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept. Transplantation. 2021 11 01; 105(11):e259-e260.